Correlation of TIMP1-MMP2/MMP9 Gene Expression Axis Changes with Treatment Efficacy and Survival of NSCLC Patients

In the course of lung cancer, normal cells are transformed into cancerous ones, and changes occur in the microenvironment, including the extracellular matrix (ECM), which is not only a scaffold for cells, but also a reservoir of cytokines, chemokines and growth factors. Metalloproteinases (MMPs) are among the elements that enable ECM remodeling. The publication focuses on the problem of changes in the gene expression of MMP2, MMP9 and tissue inhibitor of metalloproteinases (TIMP1) in the blood of NSCLC patients during therapy (one year after surgical resection of the tumor). The paper also analyzes differences in the expression of the studied genes in the tumor tissue, as well as data collected in publicly available databases. The results of blood tests showed no differences in the expression of the tested genes during therapy; however, changes were observed in cancerous tissue, which was characterized by higher expression of MMP2 and MMP9, compared to non-cancerous tissue, and unchanged expression of TIMP1. Nevertheless, higher expression of each of the studied genes was associated with shorter patient survival. Interestingly, it was not only the increased expression of metalloproteinase genes, but also the increased expression of the metalloproteinase inhibitor (TIMP1) that was unfavorable for patients.

[1]  Zhaohui S. Qin,et al.  UALCAN: An update to the integrated cancer data analysis platform , 2022, Neoplasia.

[2]  L. Sequist,et al.  Lung cancer , 2021, The Lancet.

[3]  Huiping Li,et al.  Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis , 2021, BMC Cancer.

[4]  Cuicui Ge,et al.  Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: Recent progress and current challenges. , 2021, NanoImpact.

[5]  M. Martinez-Fierro,et al.  The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases , 2020, International journal of molecular sciences.

[6]  Wei Yao,et al.  Correlation between MMP2 expression in lung cancer tissues and clinical parameters: a retrospective clinical analysis , 2020, BMC Pulmonary Medicine.

[7]  M. Moses,et al.  Metalloproteinases and their roles in human cancer , 2020, Anatomical record.

[8]  A. Tan.  Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC) , 2020, Thoracic cancer.

[9]  G. Fields.  The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma , 2019, Cells.

[10]  A. Rojiani,et al.  TIMP-1-Mediated Chemoresistance via Induction of IL-6 in NSCLC , 2019, Cancers.

[11]  G. Eapen,et al.  Lung Cancer. , 2019, The Medical clinics of North America.

[12]  A. Krüger,et al.  Recognizing the Molecular Multifunctionality and Interactome of TIMP-1. , 2019, Trends in cell biology.

[13]  B. Baradaran,et al.  Role of miR‐142 in the pathogenesis of osteosarcoma and its potential as therapeutic approach , 2018, Journal of cellular biochemistry.

[14]  Lei Song,et al.  Study on the expression of p53 and MMP-2 in patients with lung cancer after interventional therapy , 2018, Oncology letters.

[15]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[16]  Arif N Ali,et al.  Matrix metalloproteinases: their functional role in lung cancer. , 2017, Carcinogenesis.

[17]  Min-Wen Zheng.  Classification and Pathology of Lung Cancer. , 2016, Surgical oncology clinics of North America.

[18]  A. Theocharis,et al.  Extracellular matrix structure. , 2016, Advanced drug delivery reviews.

[19]  Wenping Zhou,et al.  14-3-3β Promotes Migration and Invasion of Human Hepatocellular Carcinoma Cells by Modulating Expression of MMP2 and MMP9 through PI3K/Akt/NF-κB Pathway , 2016, PloS one.

[20]  Lantao Zhao,et al.  Identification of potential therapeutic targets for lung cancer by bioinformatics analysis , 2015, Molecular medicine reports.

[21]  B. Han,et al.  Placental Growth Factor Promotes Metastases of Non-Small Cell Lung Cancer Through MMP9 , 2015, Cellular Physiology and Biochemistry.

[22]  Z. Werb,et al.  Remodelling the extracellular matrix in development and disease , 2014, Nature Reviews Molecular Cell Biology.

[23]  A. Elsamanoudy,et al.  Matrix Metalloproteinase-9 Expression in Lung Cancer Patients and Its Relation to Serum MMP-9 Activity, Pathologic Type, and Prognosis , 2014, Journal of bronchology & interventional pulmonology.

[24]  M. Louka,et al.  Evaluation of matrix metalloproteinase‐2 in lung cancer , 2014, Proteomics. Clinical applications.

[25]  Jan Budczies,et al.  Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.

[26]  H. Liu,et al.  The effects of combined treatment with sevoflurane and cisplatin on growth and invasion of human adenocarcinoma cell line A549. , 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[27]  L. Uhlin‐Hansen,et al.  Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets , 2013, Tumor Biology.

[28]  D. Edwards,et al.  Matrix metalloproteinases: protective roles in cancer , 2011, Journal of cellular and molecular medicine.

[29]  C. Santiskulvong,et al.  Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix‐metalloproteinase expression , 2010, Cytoskeleton.

[30]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[31]  W. Hung,et al.  Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. , 2010, Cancer letters.

[32]  D. Edwards,et al.  The regulation of matrix metalloproteinases and their inhibitors. , 2008, The international journal of biochemistry & cell biology.

[33]  D. Boyd,et al.  Regulation of matrix metalloproteinase gene expression , 2007, Journal of cellular physiology.

[34]  M. Sporn,et al.  Regulation of matrix metalloproteinase gene expression by a retinoid X receptor-specific ligand. , 2007, Arthritis and rheumatism.

[35]  R. Dwek,et al.  The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors* , 2006, Journal of Biological Chemistry.

[36]  M. Serio,et al.  Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR. , 2004, Lung cancer.

[37]  Ivan Stamenkovic,et al.  Functional structure and composition of the extracellular matrix , 2003, The Journal of pathology.

[38]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[39]  G. Sozzi.  Molecular biology of lung cancer. , 2001, European journal of cancer.

[40]  G. González-Ávila,et al.  Matrix Metalloproteinases' Role in Tumor Microenvironment. , 2020, Advances in experimental medicine and biology.

[41]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .